Chemical Structure (Rivastigmine 01)
Rivastigmine Transdermal System Patch, Extended Release
Product Images NDC 51991-898
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Rivastigmine Transdermal System (NDC 51991-898). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Breckenridge Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Rivastigmine 02)
Figure 2 (Rivastigmine 03)
This is a table showing the concentration of Rivastigmine medication in ng/mL for different dosage strengths (13.3 mg/24 hours, 9.5 mg/24 hours, and 4.6 mg/24 hours) based on the number of patients (n) in each group (19, 22, and 22 respectively).*
Figure 3 (Rivastigmine 04)
Figure 4 (Rivastigmine 05)
Figure 5 (Rivastigmine 06)
Figure 6 (Rivastigmine 07)
Figure 7 (Rivastigmine 08)
This is a statistical analysis of a treatment using Rivastigmine Transdermal System at different dosages. The table presents LS mean differences in improvement along with p-values for statistical significance. The graph shows the results of weeks of treatment for the different dosages. The analysis is based on an adjusted analysis of covariance model.*
Figure 8 (Rivastigmine 09)
This is a clinical study regarding the effects of Rivastigmine Transdermal System on cognitive improvement. The study lasted for 16 weeks with two different treatment options (15 cm? and 5 cm?). The results were analyzed using least squares means (LS means) and standard errors, indicating statistical significance at a level of 0.05.*
Figure A (Rivastigmine 10)
Figure B (Rivastigmine 11)
This appears to be a list of body parts where a measurement or marking could be taken. There is no further information provided.*
Figure C (Rivastigmine 12)
Figure D (Rivastigmine 13)
Figure E (Rivastigmine 14)
Figure F (Rivastigmine 15)
Figure G (Rivastigmine 16)
Figure H (Rivastigmine 17)
This text appears to be a set of instructions for properly disposing of a "slide folded patch." The instructions indicate that the user should place the patch in the trash and then fold the sticky sides together into an empty pouch that has been saved. The user is advised to keep the pouch away from children and pets.*
Principal Display Panel (4.6 mg Patch Pouch Carton)
This is information about the Rivastigmine Transdermal System, which contains 30 systems, with each 5 o’ system providing 9 mg Rivastgmine to deliver 46 mg Rvastgmine every 24 hours. To use, the old patch should be removed and safely discarded, and a new patch should be applied immediately from the original pouch. The patch should not be split, and any damaged or tampered patch should not be used. For further information, please visit bpin.com or call 1-800-967-3385.*
Principal Display Panel (9.5 mg Patch Pouch Carton)
This is a medication description for Rivastigmine Transdermal System delivered via a patch containing 18mg and delivering 9.5 mg of Rivastigmine every 24 hours, meant for transdermal use only. The instructions state that the patch should be replaced every 24 hours after removal, and the used patch should be folded and discarded safely out of the reach of children. The product should be stored at a temperature of 25°C and should not be used if damaged or showing signs of tampering. There is a phone number provided for more information.*
Principal Display Panel (13.3 mg Patch Pouch Carton)
Rivastigmine Transdermal System is a transdermal patch that delivers 13.3 mg of rivastigmine every 24 hours. The package contains 30 systems, each containing 27 mg of rivastigmine. The inactive components of the system include acrylate adhesive, acrylates copolymer, and silicon adhesive. Transdermal use is recommended, and the patch should be applied immediately after removal from the pouch. It should not be stored unpouched and must be kept out of reach of children. In case of damage or signs of tampering, do not use the patch. For further information, visit the website or call the provided number. Dosage and administration instructions can be found in the package insert.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
